SCHEMBL4708012

SCHEMBL4708012

CCn1nc(-c2ccccc2)c(C(C)=O)c(Nc2ccc(OC)c(Cl)c2)c1=O

nearest known ligand 0.67

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
PDE4B Q07343 1/20 0.67
ADRA1D P25100 5/20 0.48
ADRA1A P35348 5/20 0.48
ADRA1B P35368 5/20 0.48
HTR1A P08908 4/20 0.48
USP2 O75604 1/20 0.46
THRB P10828 1/20 0.46
MAPT P10636 4/20 0.45
TP53 P04637 1/20 0.45
GRM4 Q14833 1/20 0.44
ALDH1A1 P00352 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
MEN1 O00255 1/20 0.42
LMNA P02545 1/20 0.42
KMT2A Q03164 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4708766 0.92 PDE4B (0.70) PDE4BADRA1DADRA1AADRA1BHTR1A
SCHEMBL4706401 0.90 PDE4B (0.68) PDE4BADRA1DADRA1AADRA1BHTR1A
SCHEMBL4708694 0.89 PDE4B (0.73) PDE4BADRA1DADRA1AADRA1BHTR1A
SCHEMBL4705519 0.88 PDE4B (0.70) PDE4BADRA1DADRA1AADRA1BHTR1A
SCHEMBL4708054 0.87 PDE4B (0.69) PDE4BADRA1DADRA1AADRA1BHTR1A
SCHEMBL4707352 0.87 PDE4B (0.69) PDE4BADRA1DADRA1AADRA1BHTR1A
SCHEMBL4708425 0.87 PDE4B (0.72) PDE4BADRA1DADRA1AADRA1BHTR1A
SCHEMBL4707899 0.85 PDE4B (0.59) PDE4BADRA1DADRA1AADRA1BHTR1A
SCHEMBL4705728 0.84 PDE4B (0.77) PDE4BADRA1DADRA1AADRA1BHTR1A
SCHEMBL4708776 0.84 PDE4B (0.80) PDE4BADRA1DADRA1AADRA1BHTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7459453-B2 Pyridazin-3(2H)-one derivatives as PDE4 inhibitors LABORATORIOS ALMIRALL, S.A. (ES) 2008-12-02 US claimed
US-20060052379-A1 Pyridazin-3(2h)-one derivatives as pde4 inhibitors LABORATORIOS ALMIRALL, S.A. (ES) 2006-03-09 US claimed
US-7459453-B2 Pyridazin-3(2H)-one derivatives as PDE4 inhibitors LABORATORIOS ALMIRALL, S.A. (ES) 2008-12-02 US disclosed
US-20080269235-A1 PYRIDAZIN-3 (2H) -ONE DERIVATIVES AS PDE4 INHIBITORS DAL PIAZ VITTORIO 2008-10-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269235-A1 PYRIDAZIN-3 (2H) -ONE DERIVATIVES AS PDE4 INHIBITORS PDE4A, PDE3A, PDE4B PDE4B 3/4885ADRA1D 65/4885ADRA1A 113/4885
US-20060052379-A1 Pyridazin-3(2h)-one derivatives as pde4 inhibitors PDE4A, PDE3A, PDE4B PDE4B 3/4885ADRA1D 65/4885ADRA1A 113/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.